TY - JOUR
T1 - Perimenopause and depression
T2 - strength of association, causal mechanisms and treatment recommendations
AU - Gyllstrom, M. Elizabeth
AU - Schreiner, Pamela J.
AU - Harlow, Bernard L.
PY - 2007/4
Y1 - 2007/4
N2 - Perimenopause represents a significant transition in a woman's life. The evidence to support an association between perimenopause and depression is mixed, yet recent prospective studies have provided stronger evidence to support such an association. Interpretation of study data are complicated by methodological issues, such as a lack of standard definition for perimenopause or depression, reducing comparability. A variety of causal factors, including psychological, genetic and physiological, have been implicated in depression during perimenopause, which lends weight to a multifactorial model. Physicians should consider initiating dialogue about menopause and symptom relief at age 40 and screening perimenopausal women for depressive symptoms. Selective serotonin reuptake inhibitors are a first line of treatment for depression, but hormone therapy could be considered for women experiencing menopausal symptoms unless there are contraindications. Future research should focus on establishing temporality and studying these potential relationships among women of different ethnicities.
AB - Perimenopause represents a significant transition in a woman's life. The evidence to support an association between perimenopause and depression is mixed, yet recent prospective studies have provided stronger evidence to support such an association. Interpretation of study data are complicated by methodological issues, such as a lack of standard definition for perimenopause or depression, reducing comparability. A variety of causal factors, including psychological, genetic and physiological, have been implicated in depression during perimenopause, which lends weight to a multifactorial model. Physicians should consider initiating dialogue about menopause and symptom relief at age 40 and screening perimenopausal women for depressive symptoms. Selective serotonin reuptake inhibitors are a first line of treatment for depression, but hormone therapy could be considered for women experiencing menopausal symptoms unless there are contraindications. Future research should focus on establishing temporality and studying these potential relationships among women of different ethnicities.
KW - depression
KW - perimenopause
UR - http://www.scopus.com/inward/record.url?scp=33947624138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947624138&partnerID=8YFLogxK
U2 - 10.1016/j.bpobgyn.2006.11.002
DO - 10.1016/j.bpobgyn.2006.11.002
M3 - Review article
C2 - 17166771
AN - SCOPUS:33947624138
SN - 1521-6934
VL - 21
SP - 275
EP - 292
JO - Best Practice and Research: Clinical Obstetrics and Gynaecology
JF - Best Practice and Research: Clinical Obstetrics and Gynaecology
IS - 2
ER -